CNS Specific Antisense Oligonucleotide Market

Market Size (2017E)

US$ 0.07 BN

Market Size (2028F)

US$ 8.5 BN

GLOBAL CAR

T CELL THERAPY MARKET

CAGR (2019–2028)

46.1%

Segmentation (Scope)

By Drug

 Approved

 Patisiran

 Nusinersen

 Inotersen

 Pipeline  IONIS-HTT Rx (RG6042)

 Hereditary transthyretin amyloidosis (hATTR)

 Spinal Muscular Atrophy

 Huntington’s Disease

Key Facts

 CNS-specific antisense oligonucleotide (ASO) market is experiencing significant growth due to the rising prevalence of neurological disorders and the increasing demand for targeted therapies.

 ASOs are short DNA or RNA molecules designed to specifically bind to messenger RNA (mRNA) and inhibit the production of disease-causing proteins.

 The CNS-specific ASO market is driven by the need for effective treatments for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Market Purview

 The CNS-specific antisense oligonucleotide (ASO) market is a rapidly growing sector focused on developing targeted therapies for neurological disorders within the central nervous system.

 This market involves the development, production, and commercialization of ASOs designed to modulate gene expression and inhibit the production of disease-causing proteins in conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and other neurodegenerative disorders.

Global CNS Specific Antisense Oligonucleotide Market (%), By Region, 2023